Masters-Israilov A, et al. - The frequency and features of onabotulinumtoxinA (onabotA) wear-off in chronic migraine (CM) were investigated via undertaking a retrospective chart review of patients (n = 143) with CM initiated on onabotA over a 2-year period. Overall 62.9% of patients (90/143) experienced wear-off. Relative to no wear-off group, the wear-off group had significantly less mean units injected per session until first documented wear-off. The most common occurrence of wear-off was reported 2-4 weeks before the next injection (43.3%) and after the very first injection (40.0%). The most common bridge therapies used in the wear-off period were intramuscular ketorolac injections (33.3%) and peripheral nerve blocks (25.6%). Based on these findings, researchers suggest clinicians to consider raising the units used from the treatment onset to diminish the frequent need for bridging therapies.